NCT05921305View on ClinicalTrials.gov

Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD

PHASE3RecruitingINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Acute Graft Versus Host Disease
Interventions
DRUG

MTX

MTX (5mg/m\^2/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR

DRUG

Corticosteroid

Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or 0.2mg/kg/day methylprednisolone).

Trial Locations (2)

100044

RECRUITING

Peking University Institute of Hematology,, Beijing

510515

RECRUITING

Nanfang Hospital, Nanfang Medical University, Guangzhou

All Listed Sponsors
lead

Peking University People's Hospital

OTHER